FDA MAHARASHTRA

Office of The Commissioner,
Food & Drugs Administration M.S.
Bandra – Kurla Complex,
Bandra (E),
Mumbai – 400 051
Date : 15/06/2018

CERTIFICATE OF GOOD MANUFACTURING PRACTICES

This Certificate conforms to the format recommended by the World Health Organization.
(General instructions and explanatory notes attached).
Certificate No.: **NEW-WHO-GMP/CERT/NKD/67644/2018/11/23789**

On the basis of the inspection carried out on **20/02/2018, 21/02/2018, 16/04/2018** and **17/04/2018** ,we certify that the site indicated on this Certificate complies with **Good Manufacturing Practices** for the dosage forms, categories and activities listed in Table 1.

1. Name of the Firm : MYLAN LABORATORIES LIMITED
   Address : **F-4 & F-12, MIDC, MALEGAON, TAL. SINNAR, NASHIK 422113 MAHARASHTRA STATE, INDIA**
2. Licence No. : **NKD89 In Form 25, NKD43 In Form 28**

Table 1

Sr.No.	Dosage Form(s)	Categor(ies)	Activity(ies)
1	Capsules	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Production, Filling, Packing, labelling, Quality Control, Quality Assurance
2	Tablets	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Production, Filling, Packing, labelling, Quality Control, Quality Assurance

The responsibility for the quality of the individual batches of the pharmaceutical products manufactured through this process lies with the manufacturer.

This certificate remains valid until 12 Jun 2021 . It becomes invalid if the activities and / or categories certified herewith are changed or if the site is no longer considered to be in compliance with GMP.

Address of certifying authority :
Food & Drug Administration, M.S.
Bandra-kurla Complex,
Bandra (E), Mumbai – 400 051
Maharashtra,INDIA.
Tel: +91-22-26592363/64
Fax: +91-22-26591959
1LYM225764420180613

Name of the Authorised person : A. T. NIKHADE

Signature :

Stamp and Date : Joint Commissioner (HQ) & Controlling Authority
Food & Drug Administration, M.S.
Bandra (E), Mumbai.
Maharashtra State, India
Date:13 Jun 2018

COMMISSIONER, FOOD AND DRUGS ADMINISTRATION MAHARASHTRA STATE

13 JUN 2018

Explanatory notes

1. This certificate which is in the format recommended by WHO, certifies the status of the site listed in point 1 of the certificate.

2. The certification number should be traceable within the regulatory authority issuing the certificate.

3. Where the regulatory authority issues a licence for the site , this number should be specified record "not applicable" in cases where there is no legal framework for the issuing of a licence.

4. Table 1
List the dosage forms, starting materials, categories and activities. Examples are given below.

Example -1

Pharmaceutical Product (s)1	Category (ies)	Activity (ies)
Dosage form (s)		
Tablets	Cytotoxic	Packaging
	Hormone	Production, Packaging, Quality control.
Injectables	Penicillin	Repackaging & Labelling.
	Cefalosporin	Aseptic preparation, Packaging, Labelling.

Example - 2.

Pharmaceutical Product (s)1	Category (ies)	Activity (ies)
Starting material (s)2		
Paracetamol	Analgesic	Synthesis, Purification, Packing, Labelling.

Use, whenever available. International Nonproprietary Names (INNs) or otherwise national nonproprietary names.

5. The certificate remains valid until the specified date. The certificate becomes invalid if the activities and/or categories certified are changed or if the site is no longer considered to be in compliance with GMP.

6. The requirements for good practices the manufacture and quality control of drugs referred to in the certificate are those included in Quality Assurance of Pharmaceuticals: a compendium of guidelines and related materials . Good manufacturing practices and inspection. Volume 2, 1999. World Health Organization, Geneva and subsequent updates.

FOOD & DRUG ADMINISTRATION MAHARASHTRA STATE

Office of the Controller Food and Drugs Administration
Madhya Pradesh

No. V/WHO-GMP/M-2/2018 / 4952 **Bhopal dated** 25-9-18

VALIDITY CERTIFICATE OF PHARMACEUTICAL PRODUCTS

This is to certify that M/s Mylan Laboratories Limited, Plot No. 11, 12 & 13, Indore SEZ, Phase-II, Pharma Zone, Sector-III, Pithampur, District - Dhar (M.P.) 454775, INDIA has applied for the revalidation of WHO GMP Certificate granted to them by this Administration vide letter No. V/WHO-GMP/M-1/2016/5491 dated 07-10-2016 (Certificate No. 7/2014 valid up to 26-09-2018)

Since application for revalidation of COPPs under WHO-GMP certification Scheme is under consideration, the validity of Certificate of Pharmaceutical Products granted shall be deemed to be valid up to 26-03-2019.

To,

M/s Mylan Laboratories Limited,
Plot No. 11, 12 & 13, Indore SEZ,
Phase-II, Pharma Zone,
Sector-III, Pithampur,
District - Dhar (M.P.) -454775, INDIA

25/9/18

Deputy Drugs Controller
Food and Drugs Administration
Madhya Pradesh

Endt. No. V/WHO-GMP/M-2/2018 **Bhopal dated**
Copy to:

Drugs Inspector, Food and Drugs Administration, District - Dhar (M.P.) for information.

Deputy Drugs Controller
Food and Drugs Administration
Madhya Pradesh

भारत सरकार-कॉर्पोरेट कार्य मंत्रालय
कम्पनी रजिस्ट्रार कार्यालय, ऑध्र प्रदेश

नाम परिवर्तन के पश्चात नया निगमन प्रमाण-पत्र

कॉर्पोरेट पहचान संख्या : U24231AP1984PLC005146

मैसर्स MATRIX LABORATORIES LIMITTED

के मामले में, मैं एतदद्वारा सत्यापित करता हूँ कि मैसर्स
MATRIX LABORATORIES LIMITTED

जो मूल रुप में दिनांक उनतीस नवम्बर उन्नीस सौ चौरासी को कम्पनी अधिनियम, 1956 (1956 का 1) के अंतर्गत मैसर्स
Harren Drugs Private Limited

के रुप में निगमित की गई थी, ने कम्पनी अधिनियम, 1956 की धारा 21 की शर्तों के अनुसार विधिवत आवश्यक विनिश्चय पारित करके तथा लिखित रुप में यह सूचित करके की उसे भारत का अनुमोदन, कम्पनी अधिनियम, 1956 की धारा 21 के साथ पठित, भारत सरकार, कम्पनी कार्य विभाग, नई दिल्ली की अधिसूचना सं.सा.का.नि 507 (अ) दिनांक 24.6.1985 एस.आर.एन B22016844 दिनांक 05/10/2011 के द्वारा प्राप्त हो गया है, उक्त कम्पनी का नाम आज परिवर्तित रुप में मैसर्स
Mylan Laboratories Limited

हो गया है और यह प्रमाण-पत्र, कथित अधिनियम की धारा 23(1) के अनुसरण में जारी किया जाता है।

यह प्रमाण-पत्र हैदराबाद मे आज दिनांक पाच अक्तूबर दो हजार ग्यारह को जारी किया जाता है।

GOVERNMENT OF INDIA - MINISTRY OF CORPORATE AFFAIRS
Registrar of Companies, Andhra Pradesh

Fresh Certificate of Incorporation Consequent upon Change of Name

Corporate Identity Number : U24231AP1984PLC005146

In the matter of M/s MATRIX LABORATORIES LIMITTED

I hereby certify that MATRIX LABORATORIES LIMITTED which was originally incorporated on Twenty Nineth day of November Nineteen Hundred Eighty Four under the Companies Act, 1956 (No. 1 of 1956) as Harren Drugs Private Limited having duly passed the necessary resolution in terms of Section 21 of the Companies Act, 1956 and the approval of the Central Government signified in writing having been accorded thereto under Section 21 of the Companies Act, 1956, read with Government of India, Department of Company Affairs, New Delhi, Notification No. G.S.R 507 (E) dated 24/06/1985 vide SRN B22016844 dated 05/10/2011 the name of the said company is this day changed to Mylan Laboratories Limited and this Certificate is issued pursuant to Section 23(1) of the said Act.

Given at Hyderabad this Fifth day of October Two Thousand Eleven.

Registrar of Companies, Andhra Pradesh

कम्पनी रजिस्ट्रार, ऑध्र प्रदेश

*Note: The corresponding form has been approved by SHASHI RAJ DARA, Deputy Registrar of Companies and this certificate has been digitally signed by the Registrar through a system generated digital signature under rule 5(2) of the Companies (Electronic Filing and Authentication of Documents) Rules, 2006.

The digitally signed certificate can be verified at the Ministry website (www.mca.gov.in).

कम्पनी रजिस्ट्रार के कार्यालय अभिलेख में उपलब्ध पत्राचार का पता :
Mailing Address as per record available in Registrar of Companies office:

Mylan Laboratories Limited
Plot No.564/A/22, Road No.92, Jubilee Hills,
Hyderabad - 500033,
Andhra Pradesh, INDIA

World Health Organization

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT

Tel. direct: +41 22 791 3654
Fax direct: +41 22 791 4730
E-mail : prequalassessment@who.int

In reply please
refer to the WHO product Ref nr: HA444

Your reference:

Mr Kameshwar Bhardwaj
General Manager - Regulatory Affairs
Matrix Laboratories Ltd
1-1-151/1
4th Floor, Sairam Towers
Alexander Road
500 003 Secunderabad
Andhara Pradesh
Inde

7 August 2008

Dear Mr Bhardwaj,

WHO Prequalification of Medicines Programme

Thank you for your letter expressing Matrix Laboratories Ltd interest to participate in the "Procedure for assessing the acceptability, in principle, of pharmaceutical products for purchase by United Nations agencies", as adopted in 2001 by the 37th World Health Organization (WHO) Expert Committee on Specifications for Pharmaceutical Preparations, and published in the WHO Technical Report Series No. 908, and amended subsequently in the forty first report, as published in the WHO Technical Report Series No. 943 in 2007.

Your company's product dossier on:

- Tenofovir/Efavirenz/Emtricitabine - 300/600/200 mg - Tablet - HA444

was received by WHO on 19 June 2008, and assigned the respective WHO Reference number. Please quote this reference number in all correspondence with WHO on the respective product.

WHO will arrange for the evaluation of the product to be conducted in accordance with the terms of the recommended norms and standards, as referred to below:

- product dossiers, as specified in the relevant guidelines for the submission of product data and information (as found on the prequalification web page www.who.int/prequal);
- manufacturing sites: Good Manufacturing Practices (GMP);
- clinical sites (if applicable): Good Clinical Practices (GCP).

If and when as a result of the above-mentioned evaluation process, any of the above-mentioned products and corresponding sites are found to meet the WHO recommended standards set forth in the Guiding Principles, such products will be included in the list of suppliers whose medicinal products, as manufactured at the specified manufacturing sites, are considered to be acceptable, in principle, for procurement by UN organizations. This list is published by WHO at [www.who.int/prequal]. Please refer to the General Notes and Disclaimer, which apply to this list accordingly.

Please note that inclusion in the list can not be construed as WHO approval or endorsement, and does not necessarily mean that the products in question will actually be procured from the suppliers listed. The list, and the WHO name, emblem and/or acronym, may not, furthermore, be used by the manufacturers or suppliers for commercial or promotional purposes.

.../...

Finally, we should like to draw your attention to the fact that the list will be reviewed and updated at regular intervals. In this regard, WHO will at regular intervals arrange for the products and manufacturing sites included in the list to be re-evaluated. If, as a result of this reassessment, it is found that a product and/or specified manufacturing site no longer complies with the WHO recommended standards, such products and manufacturing sites will be removed from the list. Failure of a manufacturer or supplier to participate in the reassessment procedure (as set forth in the above-mentioned Guiding Principles) will also lead to removal of the list.

Please note that all paper versions of documentation, product samples, CDs and surface mail to the WHO Prequalification of Medicines Programme should be sent to the following address and all packages/containers should be clearly marked as indicated below.

CONFIDENTIAL
Attention: Dr Matthias Stahl
WHO Prequalification of Medicines Programme
Product Name:

UNICEF Supply Division
UNICEF Plads – Freeport
DK-2100 Copenhagen
Denmark

Confirmation of administrative data:

WHO welcomes your company's interest in voluntarily participating in this programme. In order to facilitate the performance of evaluation in accordance with the terms of the current WHO norms and standards, as well as to foster communication between Matrix Laboratories Ltd and the WHO Prequalification Programme, please complete the enclosed form and return it, signed by the authorized person from Matrix Laboratories Ltd, to the following address:

WHO Prequalification of Medicines Programme
Attention: Prequalification Secretariat
World Health Organization
HSS/PSM/QSM
20 Avenue Appia
1211 Geneva 27
Switzerland

We look forward to receiving this information from you by 21 August 2008 at the latest.

For further information regarding the submitted dossier of product **HA444** please use the email address – **prequalassessment@who.int** – and kindly ensure that any such email mentions the corresponding WHO product reference number. Kindly note that due to confidentiality and security reasons dossier information should not be submitted by email.

Your cooperation is appreciated.

Yours sincerely,

Dr Raul Kiivet
Manager, Prequalification Programme
Quality Assurance and Safety: Medicines
Department of Medicines Policy and Standards

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 209670

TENTATIVE APPROVAL

Mylan Pharmaceuticals Inc.
U.S. Agent for Mylan Laboratories Limited, India
Attention: Robert A. Barto
Senior Director, Principal Regulatory Affairs Officer
781 Chestnut Ridge Road
P.O. Box 4310
Morgantown, WV 26504-4310

Dear Mr. Barto:

Please refer to your New Drug Application (NDA) dated and received February 2, 2017, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, for the following drug product:

- Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate Tablets, 50 mg/300 mg/300 mg

This NDA provides for the use of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate Tablets for the treatment of HIV-1 infection alone as a complete regimen in adults and pediatric patients weighing 40 kg and greater.

This NDA was reviewed under the President's Emergency Plan for AIDS Relief (PEPFAR).

We completed our review of this application. It is **tentatively approved** under 21 CFR 314.105 for use as recommended in the enclosed agreed-upon labeling (refer to the enclosed text for the package insert, patient package insert, and immediate container label). Also refer to the agreed-upon labeling submitted on August 1, 2017, for the package insert and patient package insert and your July 17, 2017, submission for the revised immediate container label. Based on the data provided, the expiration dating period is 24 months for Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate Tablets, 50 mg/300 mg/300 mg in HDPE bottles containing 30, 90, or 180 tablets with desiccant, induction seal, and non-child-resistant cap when stored below 30°C (86°F).

This determination is based upon information available to the Agency at this time [i.e., information in your application and the status of current good manufacturing practices (cGMPs) of the facilities used in manufacturing and testing of the drug product]. This determination is subject to change on the basis of any new information that may come to our attention.

The listed drugs [Tivicay (dolutegravir), Viread (tenofovir disoproxil fumarate)] upon which you base your application are subject to a period of patent and/or exclusivity protection and therefore, final approval of your application under section 505(c)(3) of the Act [21 U.S.C. 355(c)(3)] may not be made effective until the period has expired.

To obtain final approval of this application, submit an amendment two or six months prior to the: 1.) expiration of the patent(s) and/or exclusivity protection or 2.) date you believe that your NDA will be eligible for final approval, as appropriate. In your cover letter, clearly identify your amendment as **"REQUEST FOR FINAL APPROVAL."** This amendment should provide the legal/regulatory basis for your request for final approval and should include a copy of any relevant court order or judgment settlement, or licensing agreement, as appropriate. In addition to a safety update, the amendment should also identify changes, if any, in the conditions under which your product was tentatively approved, i.e., updated labeling; chemistry, manufacturing, and controls data. This amendment should include draft final printed labels and labeling which comply with all U.S. regulations (uniqueness of drug product appearance per 21 CFR 206; child-resistant packaging per 16 CFR 1700, etc.). If there are no changes, clearly state so in your cover letter. Any changes require our review before final approval and the goal date for our review will be set accordingly.

We remind you that you are expected to comply with the reporting requirements provided in 21 CFR 314.80 and 314.81. If the product is to be mass distributed in developing countries, a system of collecting and reporting adverse drug reactions by the distributor would be desirable (e.g., through governmental or nongovernmental agencies distributing the products).

We also remind you that if you intend to market this product in the United States after the period of patent and exclusivity protection expires, final approval of your application will require that you comply with all applicable U.S. legislation, including the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), which requires that all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration contain a pediatric assessment unless this requirement is waived, deferred, or inapplicable. A pediatric assessment contains data gathered from pediatric studies using appropriate formulations for each age group for which the assessment is required, and other data that are adequate to: 1.) assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and 2.) support dosing and administration for each pediatric subpopulation for which the product has been assessed to be safe and effective. You must also join the antiretroviral pregnancy registry at that time and make the appropriate labeling change that references the existence of the pregnancy registry. In addition, an updated package insert (PI) must be submitted under the Structured Product Labeling requirements (http://www.fda.gov/oc/datacouncil/spl.html) as defined by the Physician's Labeling Rule [21 CFR 201.56, 201.57].

Until we issue a final approval letter, this NDA is not deemed approved.

Please note that this drug product may not be marketed in the United States without final Agency approval under Section 505 of the Act. The introduction or delivery for introduction into

interstate commerce of this drug product before the final approval date is prohibited under Section 501 of the Act and 21 U.S.C. 331(d).

If you have any questions, please contact Monica Zeballos, Pharm.D., Senior Program Consultant, at (301) 796-0840 or email at monica.zeballos@fda.hhs.gov.

Sincerely yours,

{See appended electronic signature page}

Jeffrey Murray, M.D., M.P.H.
Deputy Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosures:
Content of Labeling
Container Labeling

World Health Organization

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT

Tel. direct: +41 22 791 3717
Fax direct: +41 22 791 4730
E-mail : prequalassessment@who.int

In reply please
refer to the WHO product Ref N°: HA466

Your reference:

Mr Kameshwar Bhardwaj
Senior General Manager - Regulatory Affairs
Matrix Laboratories Limited
1-1-151/1, 4th floor
Sairam Towers
Alexander Road
Secunderabad 500 003
Inde

11 February 2011

Dear Mr Bhardwaj,

WHO Prequalification of Medicines Programme

This is in reference to your letter expressing Matrix Laboratories Limited 's interest to participate in the "Procedure for assessing the acceptability, in principle, of pharmaceutical products for purchase by United Nations agencies", as adopted in 2001 by the Thirty-seventh World Health Organization (WHO) Expert Committee on Specifications for Pharmaceutical Preparations, and amended subsequently in the Forty-first report, as published in the WHO Technical Report Series N° 943 in 2007.

Thank you for submitting the data and information requested and for voluntary participation in this quality assessment procedure. The review of your company's product dossier on:

- Tenofovir Disoproxil Fumarate /Lamivudine/Efavirenz 300mg/300mg/600mg Tablets

has been completed and following inspection of the facilities used for the manufacture and testing of this product, it has been found to meet the norms and standards recommended by WHO, and is acceptable in principle for procurement by UN agencies.

This conclusion is based on information available to WHO at this time, i.e. the information in the submitted dossier and on the status of current good manufacturing, clinical and laboratory practices at the facilities used for the manufacture and testing of the product. Please note, however, that this decision may change based on new information that may become available to us.

Thus, in accordance with and subject to the Guiding Principles of Prequalification, the product will now be included in the list of medicinal products, as manufactured at the specified manufacturing sites, which are considered to be acceptable, in principle, for procurement by UN organizations. This list is published by WHO at www.who.int/prequal.

Please note that inclusion in the list cannot be construed as WHO approval or endorsement, and does not necessarily mean that the listed products will actually be procured from the suppliers listed. The list, and the WHO name, emblem and/or acronym, may not, furthermore, be used by the applicants, manufacturers, suppliers or any other parties for commercial or promotional purposes.

The applicants and the manufacturers of prequalified products are required to communicate details to WHO of any changes in manufacture or control that may have an impact on the safety, efficacy and/or quality of the product.

ENCL: (2)

.../...

Prior to implementation of any changes in any parts of the approved dossier and/or in the manufacture of the product, please:

- consult the "Guidance on variations to a prequalified product dossier", as adopted in 2006 by the WHO Expert Committee on Specifications for Pharmaceutical Preparations, and published in Annex 6 of the WHO Technical Report Series N° 943 in 2007, and
- submit the respective information about the intended variations and the required additional data by email to – "prequalassessment@who.int", and in hard copy, clearly marked as indicated below, to the following address:

  CONFIDENTIAL
  Attention: Dr Matthias Stahl
  WHO Prequalification of Medicines Programme

  UNICEF Supply Division
  UNICEF Plads – Freeport
  2100 Copenhagen
  Denmark

Finally, we should like to draw your attention to the fact that the list will be reviewed and updated at regular intervals. In this regard WHO will, at regular intervals, arrange for the products and manufacturing sites included in the list to be re-evaluated. If, as a result of this reassessment, it is found that a product and/or specified manufacturing site no longer complies with the WHO recommended standards, such products and manufacturing sites will be removed from the list. Failure of an applicant or a manufacturer to participate in the reassessment procedure (as set forth in the above-mentioned Guiding Principles) will also lead to removal from the list.

WHO welcomes your company's voluntary participation in this programme. In order to meet the terms established for monitoring and re-evaluation of prequalified medicinal products, as well as to foster communication between Matrix Laboratories Limited and the WHO Prequalification of Medicines Programme, please complete the two forms enclosed (*"Main characteristics of the prequalified medicinal product"* and *"Undertakings of the applicant"*), and return these, signed by a duly authorized representative of Matrix Laboratories Limited, to the following address:

World Health Organization
Attention: Prequalification Secretariat
WHO Prequalification of Medicines Programme
HSS/PSM/QSM
20 Avenue Appia
1211 Geneva 27
Switzerland.

We look forward to receiving this information from you by 25 February 2011 at the latest. For further information please use the e-mail address – prequalassessment@who.int – and kindly ensure that any correspondence mentions the corresponding WHO product reference number.

Thank you for your cooperation.

Yours sincerely,

Dr Matthias Stahl
Head of Assessments
Prequalification Programme
Quality Assurance and Safety: Medicines

World Health Organization

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT

Main characteristics of the prequalified medicinal product

(to be signed by a duly authorized representative of the applicant and returned to WHO)

1. Product WHO Reference number HA466
2. INN of active ingredient(s) Tenofovir Disoproxil Fumarate /Lamivudine/Efavirenz
3. Dosage form and strength 300mg/300mg/600mg, Tablets
4. Trade name(s) of the product (if applicable)* NA
5. Name of applicant and official address 1-1-151/1, 5th Floor, Sairam Towers, Alexander Road, Secunderabad – 500 003 Andhra Pradesh, India
6. Name of manufacturer of finished product, physical address of manufacturing site(s) (and unit, if applicable) Matrix Laboratories Limited F-4, F-12, Malegaon M.I.D.C Sinnar Nashik 422113 Maharashtra India
7. Finished product specifications (ref N° and/or version; ref to pharmacopoeia) FPSTLE012R-06 (at release) FPSTLE012S-06 (Shelf life)
8. Finished product batch size (approved) 140,000 tablets
9. Name of API manufacturer, physical address of manufacturing site(s) (and unit, if applicable)
Tenofovir Disoproxil Fumarate: **Matrix Laboratories Limited (Unit-8)** G.Chodavaram Village, Pusapatirega (M), Vizianagaram District, Andhra Pradesh, India. **Matrix Laboratories Limited (Unit-1)** Survey No.10, Gaddapotharam, Kazipally, Medak district – 502319, Andhra Pradesh, India. **Lamivudine:** **Astrix Laboratories Limited (Unit 2)** Survey No.10 & 42, Gaddapotharam, Kazipally, Medak district – 502319, Andhra Pradesh, India. **Matrix Laboratories Limited (Unit-1)** Survey No.10, Gaddapotharam, Kazipally, Medak district – 502319, Andhra Pradesh, India. **Matrix Laboratories Limited (Unit-8)** Blocks PB-4. PB-6B, PB-9, PB-1 G.Chodavaram Village, Pusapatirega (M),

Vizianagaram District, Andhra Pradesh, India. **Smruthi Organics Ltd (Unit II)** Plot No. A-27, MIDC, Chincholi Tal. Mohol Solapur-413255 India **Efavirenz** **Matrix Laboratories Limited (Unit-8)** G.Chodavaram Village, Pusapatirega (M), Vizianagaram District, Andhra Pradesh, India.
10.1. API specifications (ref N° and/or version; ref to pharmacopoeia) **Tenofovir disproxil fumarate:** RMSTDF009R-W-08; **Efavirenz:** RMSEFZ079R-W-03; **Lamivudine:** RMSLMD021R-W-04
10.2. Retest period of the API(s)
Tenofovir Disproxil Fumarate: 30 months when stored between 2°C-8°C Lamivudine: 60 months when stored below 30°C Efavirenz: 24 months when stored below 30°C, tightly closed container, protected from light
11. Product description (as in finished product specifications, i.e. coated, scored, etc) White coloured, capsule shaped, film coated tablets debossed with "M 152" on one side and plain on other side.
12. Pack size(s), primary and secondary packaging material(s) The primary packs are round, white, opaque, induction-sealed 100cc HDPE bottles fitted with 38mm white polypropylene screw cup and containing a molecular sieve sachet. Pack size(s): 30 tablets
13. Storage conditions Do not store above 30°C. Store in the original container. Protect from light
14. Shelf-life 24 months

* Trade names are not prequalified - completed for WHO administrative purposes only.

I, the undersigned, certify, that the information provided above is correct and true.



Signed on behalf of Matrix Laboratories Limited.

28-02-2011 (Date)

Kameshwar Bhardwaj
Associate Vice President - DRA (Name and title)

Undertakings of the applicant

(to be signed by a duly authorized representative of the applicant and returned to WHO)

1. Matrix Laboratories Limited **hereby confirms that it:**

a) will inform the WHO Prequalification Programme in writing of any variations in the manufacture of Tenofovir Disoproxil Fumarate /Lamivudine/Efavirenz 300mg/300mg/600mg Tablets, including in particular (but not limited to) those specified in the "Main characteristics of the prequalified medicinal product", according to *Guidance on variations to a prequalified product dossier*. Geneva, World Health Organization, 2007, Annex 6 (WHO Technical Report Series, No. 943);

b) will submit the draft WHOPAR for Tenofovir Disoproxil Fumarate /Lamivudine/Efavirenz 300mg/300mg/600mg Tablets according to the current guidance notes (available at www.who.int/prequal);

c) has nominated a responsible employee (as detailed below) in Matrix Laboratories Limited responsible for communication with WHO on any issues related to the prequalified Tenofovir Disoproxil Fumarate /Lamivudine/Efavirenz 300mg/300mg/600mg Tablets, and will inform WHO of any change of contact person;

Name and title of designated contact person	
<to be entered by company>	Kameshwar Bhardwaj AVP - DRA
E-mail address, telephone number and fax number of contact person	
<to be entered by company>	kameshwar.bhardwaj@matrixlabsindia.com Ph: +91 8008001460 Fax No: +91 40 30493199

d) authorizes WHO to publish on the WHO Prequalification web site the information as listed in points 1 to 6, point 9 and 11 to 14 of the attached "Main characteristics of the prequalified medicinal product";

e) confirms that subject to the protection of any confidential and proprietary information of the applicant, manufacturer and/or CRO, WHO shall be entitled to use and publish the product and site evaluation information;

f) furthermore confirms that WHO shall also be entitled to share the full evaluation and inspection reports with the relevant authorities of any interested WHO Member State.

2. Commitments:

2.1. The Applicant committed in the dossier that at least one batch per year of the product will be placed on the on-going stability programme. Unless otherwise justified, at least one batch per year of the product manufactured in every primary packaging type should be included in the stability programme (unless none is produced during that year). The stability protocol is confirmed to be that which was approved for primary batches. Out-of-specification results or significant atypical trends should be investigated. Any confirmed significant change, out-of-specification result, or significant atypical trend should be reported immediately to WHO. The possible impact on batches on the market should be considered in consultation with WHO inspectors.

2.2. The Applicant committed (letter dated 8 October 2010) to place the first three batches of any batch size larger than 140,000 tablets at accelerated test conditions (40 ± 2^0C/75 ± 5% RH) up to 6 months & at long term test conditions (30 ± 2^0C/75 ± 5% RH) up to 36 months as per the approved protocol for primary batches. The Applicant committed to report any out of specification results immediately to WHO.

Signed on behalf of Matrix Laboratories Limited.

28-02-2011 (Date)

Kameshwar Bhardwaj

Associate Vice President - DRA (Name and title)